News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Exelixis (EXEL) reported its Q2 2026 earnings, with total revenues reaching $628.7 million, a 10.6% increase year-over-year, driven by cabozantinib sales. The company updated its full-year 2026 revenue guidance downwards due to a more gradual sales ramp in the neuroendocrine tumor indication but reduced …
Annex Advisory Services LLC has acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL), purchasing 25,918 shares valued at approximately $1.41 million during the second quarter. This investment comes as Exelixis reported strong quarterly earnings, surpassing EPS expectations, though revenue slightly missed analyst estimates. Despite …
Argus has lowered its target price for Exelixis Inc. (EXEL) to $56.00, while the current price stands at $50.44. Exelixis is a biopharmaceutical company focused on discovering, developing, and commercializing cancer treatments.
Exelixis director Mary Beckerle sold 9,812 shares of the company's common stock for over $526,000, executed under a Rule 10b5-1 trading plan. This transaction leaves her with 16,079 beneficially owned shares, including RSUs. The sale occurred as Exelixis's stock saw a recent decline but …
Exelixis (NASDAQ:EXEL) Director Mary Beckerle sold 9,812 shares of company stock, valued at $526,511.92, under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced her ownership by 37.9% to 16,079 shares. The biotechnology company recently reported strong quarterly earnings, beating analyst estimates with $0.91 …
Exelixis director Mary C. Beckerle sold 9,812 shares of common stock on August 10, 2026, at a weighted average price of $53.66 per share, under a pre-arranged Rule 10b5-1 trading plan. Following this transaction, Beckerle's holdings consist of 16,079 shares, which are to be …
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have disclosed a beneficial ownership of 11,023,943 shares of Exelixis, Inc. common stock, representing 4.39% of the class. The filing indicates shared voting power over 10,935,221 shares and shared dispositive power over all 11,023,943 …
SueWallSt is investigating potential securities claims against Exelixis (NASDAQ: EXEL) following a reduction and narrowing of its full-year 2026 revenue guidance. The company's shares declined after it cited a slower-than-expected ramp in its neuroendocrine-tumor business, contradicting earlier reiterations of its financial outlook. Shareholders who …
Levi & Korsinsky, LLP has announced an investigation into Exelixis (EXEL) after the company reiterated its full-year 2026 financial guidance on May 5, 2026, only to lower and narrow its revenue outlook weeks later, causing a stock decline. The investigation focuses on whether Exelixis …
This article reports on an SEC Form 144 filing by Exelixis, Inc. (EXEL) on August 10, 2026. The filing indicates a proposed sale of 9,812 shares of common stock with an aggregate market value of $526,496.22, acquired on May 29, 2026, through a restricted …
This article analyzes Exelixis Inc. (NASDAQ: EXEL) using AI models to provide institutional trading strategies. It highlights a weak near-term sentiment but strong long-term outlook, with a significant 26.9:1 risk-reward setup. Three distinct strategies—Position Trading, Momentum Breakout, and Risk Hedging—are detailed, alongside multi-timeframe signal …
EXELIXIS ($EXEL) announced its Q2 2026 earnings, reporting $0.91 per share, which surpassed estimates. However, the company's revenue of $628.69 million fell short of expectations. Following the announcement, the stock experienced a 5.23% decline.
Exelixis, Inc.'s average stock price target has been raised from $52.25 to $52.62 by 16 analysts, suggesting a potential 7% downside based on the August 5 closing price. Despite the raised target implying a decrease, the consensus rating for EXEL remains a "Buy" from …
Exelixis reported Q4 2025 revenues of $599M, primarily driven by a 6% year-over-year increase in U.S. CABOMETYX sales to $547M, with full-year 2025 U.S. CABOMETYX revenue reaching $2.12B, up 17% year-over-year. The company is preparing for a potential late 2026 launch of zanzalintinib for …
Quantinno Capital Management LP significantly increased its stake in Exelixis, Inc. by 44.3% in the first quarter, now holding 115,592 shares valued at approximately $4.96 million. This increase occurred despite mixed analyst ratings and recent insider selling. Exelixis reported strong second-quarter adjusted earnings but …
Leerink Partners has downgraded its rating for Exelixis Inc (EXEL.O) from "Outperform" to "Market Perform." This change indicates a revised outlook on the pharmaceutical company's stock performance. The update was reported by Reuters.
Exelixis (EXEL) saw its stock drop 6.7% after cutting its 2026 revenue outlook to $2.50 billion–$2.55 billion. This revision came despite solid Q2 earnings and is attributed to slower growth in the neuroendocrine tumor indication and continued heavy investment in its zanzalintinib pipeline and …
EXELIXIS, INC. reported strong second-quarter 2026 results with revenue of $628.69M and diluted EPS of $0.82, showing significant year-over-year growth due to increased product demand and price gains. Key drivers included CABOMETYX sales, progress in pipeline development with zanzalintinib, and expanded clinical trials. The …
Exelixis Inc (EXEL) reported strong financial results for Q2 2026, surpassing analyst expectations with total revenues of $628.7 million and a GAAP diluted EPS of $0.82. The biopharmaceutical company, known for its cancer treatments like cabozantinib, updated its fiscal year 2026 guidance, projecting total …
Exelixis, Inc. published its Q2 2026 earnings call presentation. The company reported EPS of $0.91, beating estimates by $0.02, but revenue of $628.69M missed expectations by $7.46M, despite a 10.63% year-over-year increase. The slide deck provides detailed information discussed during the earnings call.
Exelixis, Inc. (EXEL) reported mixed results for Q2 2026, beating earnings estimates with 82 cents EPS but missing revenue forecasts at $628.7 million. The company lowered its full-year 2026 revenue guidance due to a slower-than-expected ramp-up of its neuroendocrine tumor indication for Cabometyx. Despite …
Search by ticker symbol or company name and select a result to open its chart.